MedPath

A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

Phase 4
Completed
Conditions
Influenza
Interventions
Biological: Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine
Biological: Fluad_MF59-adjuvanted trivalent influenza subunit vaccine
Registration Number
NCT01222403
Lead Sponsor
Novartis Vaccines
Brief Summary

This study will evaluate the safety of an influenza (flu) vaccine in Korean men and women aged 65 years and older.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
767
Inclusion Criteria
  1. Males and females aged 65 years and above on the day of enrollment, who were eligible for seasonal influenza vaccination.
  2. In the judgement of the study doctor are determined to be in reasonable health considering their age and able to comply with all study procedures.
Exclusion Criteria
  1. History of any serious reaction to flu vaccine, or any materials in the vaccine, and to eggs (including ovalbumin) and chicken protein.
  2. Receipt of another (inactivated) vaccine within 2 weeks, or receipt of a live vaccine within 4 weeks prior to Study Day 1, or planning to receive some other vaccination before the final study visit (about Day 29 after vaccination).
  3. Any condition, which in the opinion of the study doctor, might interfere with the evaluation of the study objective.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Vantaflu_aTIVVantaflu_MF59-adjuvanted trivalent influenza subunit vaccineSubjects aged \>65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
FluadFluad_MF59-adjuvanted trivalent influenza subunit vaccineSubjects aged \>65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
Primary Outcome Measures
NameTimeMethod
Number of Subjects Reporting Solicited Adverse Events (AEs) After Vaccination.Day 1 through Day 4 after vaccination

The number of subjects reporting any solicited local and systemic AEs, following vaccination with Fluad_aTIV and Vantaflu_aTIV.

Number of Subjects Reporting Unsolicited AEs After Vaccination.Day 1 through Day 28 post vaccination

The number of subjects reporting any unsolicited AEs following vaccination with Fluad_aTIV and Vantaflu_aTIV.

Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs) After Vaccination.Day 1 through Day 28 post vaccination

The number of subjects reporting any unsolicited AEs, SAEs, AEs leading to withdrawal (WD), AEs of special interest (AESI) following vaccination with Fluad_aTIV and Vantaflu_aTIV.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (22)

Ju Saengmyeong internal medicine Clinic

🇰🇷

Daejeon, Korea, Republic of

Jiguchon internal medicine Clinic

🇰🇷

Jeongeup, Jeonrabuk-do, Korea, Republic of

Daejeon hospital

🇰🇷

Daejeon, Korea, Republic of

Yonsei Universtity College of Medicine

🇰🇷

Sinchon-dong, Seoul, Korea, Republic of

Hangajok internal medicine clinic

🇰🇷

Daejeon, Korea, Republic of

KeeTaek Kim internal medicine Clinic

🇰🇷

Gimpo-si, Gyeonggi-do, Korea, Republic of

21th Century hana internal medicine clinic

🇰🇷

Mokpo, Jeonranam-do, Korea, Republic of

JoongAng family medicine Clinic

🇰🇷

Suncheon, Jeonranam-do, Korea, Republic of

TaeIl Jang internal medicine Clinic

🇰🇷

Incheon, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Yonsei University Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Gikim internal medicine clinic

🇰🇷

Seoul, Korea, Republic of

SaeSeoul internal medicine and radiology Clinic

🇰🇷

Daejeon, Korea, Republic of

SeoIncheon catholic clinic

🇰🇷

Incheon, Korea, Republic of

SeokYeon Kim internal medicine clinic

🇰🇷

Incheon, Korea, Republic of

Yeonsei Koum internal medicine Clinic

🇰🇷

Seoul, Korea, Republic of

Soon Chun Hyang University Hospital

🇰🇷

Seoul, Korea, Republic of

Lee internal medicine clinic

🇰🇷

Seoul, Korea, Republic of

Kangnam Sacred Heart Hospital

🇰🇷

Seoul, Korea, Republic of

Korea University Guro Hospital

🇰🇷

Seoul, Korea, Republic of

Global care internal medicine clinic

🇰🇷

Seoul, Korea, Republic of

Seoul medical center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath